Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 39.28 Million EUR | 41.6% |
| 2022 | 27.74 Million EUR | 163.34% |
| 2021 | 10.53 Million EUR | -11.71% |
| 2020 | 11.93 Million EUR | 34.05% |
| 2019 | 8.9 Million EUR | -56.82% |
| 2018 | 20.61 Million EUR | -13.76% |
| 2017 | 23.9 Million EUR | 7.88% |
| 2016 | 22.15 Million EUR | -3.62% |
| 2015 | 22.99 Million EUR | -5.79% |
| 2014 | 24.4 Million EUR | 9.77% |
| 2013 | 22.23 Million EUR | -5.4% |
| 2012 | 23.5 Million EUR | -7.14% |
| 2011 | 25.3 Million EUR | -13.32% |
| 2010 | 29.19 Million EUR | 21.46% |
| 2009 | 24.03 Million EUR | -9.08% |
| 2008 | 26.44 Million EUR | 36.79% |
| 2007 | 19.32 Million EUR | 79.32% |
| 2006 | 10.77 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | -100.0% |
| 2003 | 9.28 Million EUR | 35.38% |
| 2002 | 6.85 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 43.47 Million EUR | 10.66% |
| 2024 Q3 | 47.76 Million EUR | 1.09% |
| 2024 Q2 | 47.24 Million EUR | 8.67% |
| 2023 Q4 | 39.28 Million EUR | 12.6% |
| 2023 Q2 | 35.55 Million EUR | 9.02% |
| 2023 Q1 | 32.61 Million EUR | 17.56% |
| 2023 FY | 39.28 Million EUR | 41.6% |
| 2023 Q3 | 34.89 Million EUR | -1.88% |
| 2022 Q2 | 18.59 Million EUR | 18.16% |
| 2022 Q4 | 27.74 Million EUR | 29.01% |
| 2022 FY | 27.74 Million EUR | 163.34% |
| 2022 Q1 | 15.73 Million EUR | 49.33% |
| 2022 Q3 | 21.5 Million EUR | 15.69% |
| 2021 Q4 | 10.53 Million EUR | -0.03% |
| 2021 FY | 10.53 Million EUR | -11.71% |
| 2021 Q1 | 8.72 Million EUR | -26.91% |
| 2021 Q2 | 10.74 Million EUR | 23.18% |
| 2021 Q3 | 10.53 Million EUR | -1.91% |
| 2020 Q2 | 9.57 Million EUR | 9.75% |
| 2020 Q1 | 8.72 Million EUR | -1.99% |
| 2020 FY | 11.93 Million EUR | 34.05% |
| 2020 Q4 | 11.93 Million EUR | 39.18% |
| 2020 Q3 | 8.57 Million EUR | -10.46% |
| 2019 Q4 | 8.9 Million EUR | 4.23% |
| 2019 Q1 | 9.96 Million EUR | -51.65% |
| 2019 Q2 | 9.08 Million EUR | -8.81% |
| 2019 Q3 | 8.54 Million EUR | -6.03% |
| 2019 FY | 8.9 Million EUR | -56.82% |
| 2018 Q4 | 20.61 Million EUR | 3.74% |
| 2018 FY | 20.61 Million EUR | -13.76% |
| 2018 Q1 | 26.84 Million EUR | 12.31% |
| 2018 Q2 | 25.9 Million EUR | -3.52% |
| 2018 Q3 | 19.87 Million EUR | -23.27% |
| 2017 Q4 | 23.9 Million EUR | 3.28% |
| 2017 FY | 23.9 Million EUR | 7.88% |
| 2017 Q3 | 23.14 Million EUR | -6.16% |
| 2017 Q2 | 24.66 Million EUR | -2.41% |
| 2017 Q1 | 25.27 Million EUR | 14.05% |
| 2016 Q1 | 24.95 Million EUR | 8.55% |
| 2016 Q4 | 22.15 Million EUR | -3.66% |
| 2016 FY | 22.15 Million EUR | -3.62% |
| 2016 Q2 | 24.78 Million EUR | -0.7% |
| 2016 Q3 | 22.99 Million EUR | -7.19% |
| 2015 Q2 | 27.17 Million EUR | -5.09% |
| 2015 Q1 | 28.63 Million EUR | 17.35% |
| 2015 FY | 22.99 Million EUR | -5.79% |
| 2015 Q3 | 26.29 Million EUR | -3.25% |
| 2015 Q4 | 22.99 Million EUR | -12.57% |
| 2014 FY | 24.4 Million EUR | 9.77% |
| 2014 Q4 | 24.4 Million EUR | 0.83% |
| 2014 Q3 | 24.2 Million EUR | -3.58% |
| 2014 Q2 | 25.1 Million EUR | -2.69% |
| 2014 Q1 | 25.79 Million EUR | 16.03% |
| 2013 Q2 | 27.11 Million EUR | -1.01% |
| 2013 FY | 22.23 Million EUR | -5.4% |
| 2013 Q3 | 23.55 Million EUR | -13.12% |
| 2013 Q4 | 22.23 Million EUR | -5.61% |
| 2013 Q1 | 27.38 Million EUR | 16.54% |
| 2012 Q2 | 27.2 Million EUR | -5.37% |
| 2012 Q1 | 28.74 Million EUR | 13.59% |
| 2012 Q3 | 25.3 Million EUR | -6.97% |
| 2012 FY | 23.5 Million EUR | -7.14% |
| 2012 Q4 | 23.5 Million EUR | -7.14% |
| 2011 Q4 | 25.3 Million EUR | -8.55% |
| 2011 FY | 25.3 Million EUR | -13.32% |
| 2011 Q1 | 30.32 Million EUR | 3.86% |
| 2011 Q2 | 30.07 Million EUR | -0.83% |
| 2011 Q3 | 27.67 Million EUR | -7.97% |
| 2010 FY | 29.19 Million EUR | 21.46% |
| 2010 Q1 | 26.97 Million EUR | 12.22% |
| 2010 Q2 | 27.2 Million EUR | 0.85% |
| 2010 Q3 | 24.61 Million EUR | -9.51% |
| 2010 Q4 | 29.19 Million EUR | 18.6% |
| 2009 Q4 | 24.03 Million EUR | -7.84% |
| 2009 FY | 24.03 Million EUR | -9.08% |
| 2009 Q1 | 29.07 Million EUR | 9.98% |
| 2009 Q3 | 26.08 Million EUR | 0.0% |
| 2009 Q2 | - EUR | -100.0% |
| 2008 Q4 | 26.44 Million EUR | 0.0% |
| 2008 FY | 26.44 Million EUR | 36.79% |
| 2007 FY | 19.32 Million EUR | 79.32% |
| 2006 FY | 10.77 Million EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | -100.0% |
| 2003 FY | 9.28 Million EUR | 35.38% |
| 2002 FY | 6.85 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Atrys Health, S.A. | 1.67 Million EUR | -2242.815% |
| Biotechnologies Assets SA | -3.15 Million EUR | 1345.109% |
| Laboratorios Farmaceuticos Rovi, S.A. | 337.96 Million EUR | 88.375% |